Current Drug Targets


Francis J. Castellino
(14643 citations)
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556

Personal Subscription
Become EABM
Become Reviewer

Preface promotion: free to download

Volume:3   Issue: 6
Pp: i-i
George J. Christ
DOI: 10.2174/1389450023347407

Gap Junction Synthesis and Degradation as Therapeutic Targets

Volume:3   Issue: 6
Pp: 409-416
Eric C. Beyer and Viviana M. Berthoud
DOI: 10.2174/1389450023347245

The Physiology, Pathophysiology and Therapeutic Potential of Gap Junctions in Smooth Muscle

Volume:3   Issue: 6
Pp: 427-440
G. Lagaud, K.P. Davies, K. Venkateswarlu and G. J. Christ
DOI: 10.2174/1389450023347399

Mutagenic Approaches to Modifying Gap Junction Phenotype

Volume:3   Issue: 6
Pp: 441-453
S. N. Zucker and B. J. Nicholson
DOI: 10.2174/1389450023347218

Prospects for Rational Development of Pharmacological Gap Junction Channel Blockers

Volume:3   Issue: 6
Pp: 455-464
David C. Spray, Renato Rozental and Miduturu Srinivas
DOI: 10.2174/1389450023347353

Gap Junctions as Targets for Cancer Chemoprevention and Chemotherapy

Volume:3   Issue: 6
Pp: 465-482
J.E. Trosko and R.J. Ruch
DOI: 10.2174/1389450023347371

Connexin-GFPs Shed Light on Regulation of Cell-Cell Communication by Gap Junctions

Volume:3   Issue: 6
Pp: 483-499
Vytas K. Verselis and Feliksas F. Bukauskas
DOI: 10.2174/1389450023347272